US Stock MarketDetailed Quotes

QDEL QuidelOrtho

Watchlist
  • 42.290
  • -0.170-0.40%
Trading Dec 19 10:19 ET
2.84BMarket Cap-1.52P/E (TTM)

QuidelOrtho Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

QuidelOrtho Q3 2024 Earnings Date

Currency：USDNov 7, 2024

Estimate
(YoY)		 Actual
(YoY)		 Vs Estimate
(% Chg)
Revenue
643.52M
727.10M
+83.58M
Beat Est.
-13.51%
-2.27%
+12.99%
EPS
-0.55
-0.30
+0.25
Beat Est.
-188.15%
-57.89%
+45.18%
Analyst Rating
Buy

Dec 11, 2024

QuidelOrtho Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 7 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 705.152M--
--2024/Q4-- / 698.038M--
Nov 7, 20242024/Q3727.100M / 643.520M--
Jul 31, 20242024/Q2637.000M / 614.907M--
May 8, 20242024/Q1711.000M / 695.131M--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 705.152M--
--2024/Q4-- / 698.038M--
Nov 7, 20242024/Q3727.100M / 643.520M--
Jul 31, 20242024/Q2637.000M / 614.907M--
May 8, 20242024/Q1711.000M / 695.131M--

Unlock Free Earnings Estimates

QuidelOrtho Earnings Reports

  • QuidelOrtho | 10-Q: Q3 2024 Earnings Report

    Nov 8 13:03 ET

  • QuidelOrtho | 8-K: QuidelOrtho Reports Third Quarter 2024 Financial Results

    Nov 7 16:15 ET

  • QuidelOrtho | 10-Q: Q2 2024 Earnings Report

    Aug 1 15:17 ET

  • QuidelOrtho | 10-K/A: Annual report (Amendment)

    Aug 1 14:46 ET

    • Read more

    Trending US Stocks
    Best Growth Stocks Best Growth Stocks

    Spot stocks with huge growth potential and solid financial standing. Spot stocks with huge growth potential and solid financial standing.

    Symbol Mini Chart % Chg
    Halozyme Therapeutics
    HALO
    +1.88%
    Teradata Corp
    TDC
    +1.49%
    Hutchmed (China)
    HCM
    +1.45%
    LIFE HEALTHCARE GROUP HOLDINGS UNSPON ADR EA REPR 4 ORD ZAR0.00
    LTGHY
    +1.08%
    Dorian LPG
    LPG
    +0.81%

    Unlock the Full List

    Analysis

    Analyst Rating

    Updated: Dec 11, 2024

    Buy

    • Buy

      60.00%

    • Hold

      20.00%

    • Sell

      20.00%

    Price Target

    No Data